---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-050223"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T02:42:06.471885+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# PURE Bioscience Q1 FY2025 product sales $555K, down 23% YoY; net loss per share ($0.01)

## Summary
- Net product sales of $555K for quarter ended Oct 31, 2024, vs $718K YoY, due to budget constraints of a large end-use customer.
- Net loss narrowed to $689K from $735K YoY; net loss per share unchanged at ($0.01).
- Excluding share-based compensation, net loss was $632K vs $655K YoY.
- CEO cites unexpected interruption in product flow to a major customer and lack of replacement revenue as reasons for the decline.

## SEC filing metadata
- accession: 0001493152-24-050223
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315224050223/0001493152-24-050223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315224050223/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-050223
- JSON: https://secwatch.observer/filing/0001493152-24-050223.json
- Plain text: https://secwatch.observer/filing/0001493152-24-050223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.